Tim Reierson#Otsuka #ClickTherapeutics #FDA approved #SmartPhone #Depression app #ReJoyn press release at link.
https://otsuka-us.com/news/rejoyn-fda-authorized
As tech companies come for your sensitive emotional words & movements, please keep in mind that FDA approval for smartphone app does NOT protect your sensitive data from being taken & used.
Tech companies do the studies. Metrics show a result but gloss true complexity. Datafication of human experience is false premise. Result claimed against low bar. "In the trial, patients were randomized to receive either Rejoyn or a sham control app."
The 30 page ReJoyn privacy policy is enough to make anyone depressed.
https://www.rejoyn.com/oph-privacy-policy
That's a lot to ask of someone suffering from depression, to read and understand that document. & yes they use your data for targeted advertising, also they claim de-identification which means there will be uses made that are unknown.
This is digital scalable care. Who profits? Who pays?
#MentalHealth
Otsuka and Click Therapeutics Announce the U.S. Food and Drug Administration (FDA) Clearance of Rejoyn™, the First Prescription Digital Therapeutic Authorized for the Adjunctive Treatment of Major Depressive Disorder (MDD) Symptoms | Otsuka US
Otsuka Pharmaceutical, Co. Ltd. and Click Therapeutics, Inc., announce that the U.S. Food and Drug Administration has cleared Rejoyn™ (developed as CT-152), the first prescription digital therapeutic authorized for the treatment of major depressive disorder (MDD) symptoms as an adjunct to clinician-managed outpatient care for adult patients with MDD age 22 years and older who are on antidepressant medication. Rejoyn is intended to reduce MDD symptoms.
Dominic Tyer